Paper Details

  1. Home
  2. Paper Details

Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.

Author: CortelezziA, FritzE, GisslingerH, KuzmitsR, LinkeschW, LudwigH, PolliE, ScheithauerW, SinzingerH, Van CampB G

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 42 patients with multiple myeloma compared chemotherapy to interferon-alpha 2C treatment. Chemotherapy resulted in a significantly higher response rate (89%) compared to interferon (43%). Patients with stage I disease had better responses than those with stage II or III. In a separate group of 11 patients with high platelet count due to other conditions, interferon achieved complete remission in 7 out of 8 patients. Interferon treatment was associated with common side effects, but these could be reduced by decreasing the dose or stopping treatment.
Paper Details　
Original Abstract of the Article :
Forty-two patients with multiple myeloma were allocated to two groups to receive either polychemotherapy with vincristine, melphalan, cyclophosphamide and prednisolone, or recombinant interferon-alpha 2C monotherapy. The response rate of 43% in the interferon group was significantly lower than that ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000226080

データ提供：米国国立医学図書館（NLM）

Recombinant Interferon-Alpha-2C: A Potential Treatment for Multiple Myeloma and Thrombocythaemia

The desert of cancer treatment is vast and complex, with researchers constantly seeking new and effective therapies. This study explores the efficacy of recombinant interferon-alpha-2C in treating multiple myeloma and thrombocythaemia, evaluating its effectiveness and potential side effects. The authors conducted two separate studies, one examining the use of interferon-alpha-2C in multiple myeloma patients and the other evaluating its efficacy in patients with thrombocythaemia.

Interferon-Alpha-2C Shows Promise for Thrombocythaemia

While the study found that interferon-alpha-2C was less effective than chemotherapy in treating multiple myeloma, it showed promising results in treating thrombocythaemia. The authors noted that complete remissions were achieved in a significant proportion of patients with thrombocythaemia, suggesting that interferon-alpha-2C could be a valuable tool for managing this condition. This research underscores the potential of interferon-alpha-2C in treating specific hematological disorders, offering hope for patients facing these challenges.

The Importance of Personalized Treatment

This study highlights the importance of personalized treatment approaches in managing complex disorders like multiple myeloma and thrombocythaemia. The authors emphasize that while interferon-alpha-2C may not be effective for all patients, it could be a valuable option for those with specific conditions, such as thrombocythaemia. The findings encourage continued research to refine our understanding of interferon-alpha-2C's efficacy in different patient populations, potentially leading to more effective and personalized treatment strategies.

Dr. Camel's Conclusion

This study reminds us that the desert of cancer treatment is vast and complex, with different treatment approaches proving effective for specific conditions. The research highlights the potential of interferon-alpha-2C in treating thrombocythaemia, offering hope for patients facing this challenge. This study encourages further exploration of interferon-alpha-2C's efficacy in different patient populations, potentially leading to more effective and personalized treatment strategies.
Date :
  1. Date Completed 1986-01-28
  2. Date Revised 2018-02-16
Further Info :

Pubmed ID

4080297

DOI: Digital Object Identifier

10.1159/000226080

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.